Literature DB >> 17549633

Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity.

Stéphane Nancey1, Nadim Hamzaoui, Driffa Moussata, Ivan Graber, Jacques Bienvenu, Bernard Flourie.   

Abstract

The relationship between plasma interleukin-6 (IL-6) concentration and its soluble receptor in Crohn's disease (CD) is not well elucidated. Twenty healthy volunteers and 94 consecutive patients with CD (44 in relapse and 50 in remission) were studied. Plasma IL-6 concentrations in patients with active disease [80 +/- 9 pg/ml; mean +/- standard error of the mean (SEM)] were significantly higher than in patients with inactive disease (50 +/- 4 pg/ml; P < 0.001) or controls (3 +/- 1 pg/ml; P < 0.001). However, concentrations did not vary with the severity of CD attacks. Plasma concentrations of soluble interleukin-6 receptor (sIL-6R) in active-CD patients (77 +/- 5 ng/ml) did not differ significantly from those with inactive disease (82 +/- 5 ng/ml), while both groups had significantly raised concentrations compared with those of controls (58 +/- 6 ng/ml; P < 0.03 and P < 0.01, respectively). Plasma IL-6 concentrations correlated significantly with serum C-reactive protein (CRP) (r = 0.34; P < 0.001), whereas plasma sIL-6R concentrations did not. Taken together, these data suggest that, although IL6 and sIL6-R are both involved in the inflammatory process of CD, they are poor markers of disease activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549633     DOI: 10.1007/s10620-007-9849-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Identification of alpha 2-macroglobulin as a carrier protein for IL-6.

Authors:  T Matsuda; T Hirano; S Nagasawa; T Kishimoto
Journal:  J Immunol       Date:  1989-01-01       Impact factor: 5.422

2.  Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease.

Authors:  T Hosokawa; K Kusugami; K Ina; T Ando; M Shinoda; A Imada; M Ohsuga; T Sakai; T Matsuura; K Ito; K Kaneshiro
Journal:  J Gastroenterol Hepatol       Date:  1999-10       Impact factor: 4.029

3.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody.

Authors:  J T Beck; S M Hsu; J Wijdenes; R Bataille; B Klein; D Vesole; K Hayden; S Jagannath; B Barlogie
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

4.  [Proposal of a system of criteria for the diagnosis of cryptogenetic inflammatory enterocolitis (Crohn's disease and hemorrhagic rectocolitis). A cooperative study by the Cryptogenic Enterocolitis Study Group].

Authors:  P Bernades; P Hecketsweiler; M Benozio; L Descos; Y Geffroy; J Hemet; J Loygue; R Modigliani; F Potet; J P Weill
Journal:  Gastroenterol Clin Biol       Date:  1978-12

5.  Profile of soluble cytokine receptors in Crohn's disease.

Authors:  T Gustot; A Lemmers; E Louis; C Nicaise; E Quertinmont; J Belaiche; S Roland; A Van Gossum; J Devière; D Franchimont
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

6.  Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease.

Authors:  J S Hyams; J E Fitzgerald; W R Treem; N Wyzga; D L Kreutzer
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

7.  Elevated serum interleukin-6 levels in patients with reactive thrombocytosis.

Authors:  C W Hollen; J Henthorn; J A Koziol; S A Burstein
Journal:  Br J Haematol       Date:  1991-10       Impact factor: 6.998

8.  Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.

Authors:  J P Gaillard; R Bataille; H Brailly; C Zuber; K Yasukawa; M Attal; N Maruo; T Taga; T Kishimoto; B Klein
Journal:  Eur J Immunol       Date:  1993-04       Impact factor: 5.532

9.  Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal.

Authors:  H Suzuki; K Yasukawa; T Saito; M Narazaki; A Hasegawa; T Taga; T Kishimoto
Journal:  Eur J Immunol       Date:  1993-05       Impact factor: 5.532

10.  Soluble interleukin 6 receptor is biologically active in vivo.

Authors:  A Mackiewicz; M Wiznerowicz; E Roeb; A Karczewska; J Nowak; P C Heinrich; S Rose-John
Journal:  Cytokine       Date:  1995-02       Impact factor: 3.861

View more
  17 in total

Review 1.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 2.  Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.

Authors:  Guillaume Bouguen; Jean-Baptiste Chevaux; Laurent Peyrin-Biroulet
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

3.  Incidence of Myocardial Infarction and Cerebrovascular Accident in Patients With Hidradenitis Suppurativa.

Authors:  Sarah Reddy; Andrew Strunk; Gregor B E Jemec; Amit Garg
Journal:  JAMA Dermatol       Date:  2020-01-01       Impact factor: 10.282

4.  Subclinical intestinal inflammation in patients with Crohn's disease following bowel resection: a smoldering fire.

Authors:  Cesare Ruffolo; Marco Scarpa; Diego Faggian; Daniela Basso; Renata D'Incà; Mario Plebani; Giacomo C Sturniolo; Nicolò Bassi; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2009-11-10       Impact factor: 3.452

5.  Preoperative exercise capacity in adult inflammatory bowel disease sufferers, determined by cardiopulmonary exercise testing.

Authors:  J M Otto; A F O'Doherty; P J Hennis; K Mitchell; J S Pate; J A Cooper; M P W Grocott; H E Montgomery
Journal:  Int J Colorectal Dis       Date:  2012-07-29       Impact factor: 2.571

6.  Circulating cytokines reflect mucosal inflammatory status in patients with Crohn's disease.

Authors:  Farid Ljuca; Adnan Gegic; Nermin N Salkic; Nada Pavlovic-Calic
Journal:  Dig Dis Sci       Date:  2009-10-16       Impact factor: 3.199

7.  Susceptibility to hepatocellular carcinoma in the Chinese population--associations with interleukin-6 receptor polymorphism.

Authors:  Yan Deng; Meng Li; Jian Wang; Li Xie; Taijie Li; Yu He; Qinghua Lu; Ruolin Li; Aihua Tan; Xue Qin; Shan Li
Journal:  Tumour Biol       Date:  2014-03-26

8.  Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide-induced sickness behavior.

Authors:  Michael D Burton; Nathan L Sparkman; Rodney W Johnson
Journal:  J Neuroinflammation       Date:  2011-05-19       Impact factor: 8.322

9.  Systemic sclerosis biomarkers detection in the secretome of TGFβ1-activated primary human lung fibroblasts.

Authors:  Ryan T Kendall; Ludivine Renaud; John E Baatz; Maya Malaab; Xinh-Xinh Nguyen; Carol A Feghali-Bostwick
Journal:  J Proteomics       Date:  2021-04-27       Impact factor: 3.855

10.  Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides.

Authors:  Olga Y Korolkova; Jeremy N Myers; Samuel T Pellom; Li Wang; Amosy E M'Koma
Journal:  Clin Med Insights Gastroenterol       Date:  2015-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.